Alex Zhavoronkov, Ph.D.
Idiopathic Pulmonary Fibrosis (IPF), a devastating lung disease affecting millions with increasing incidence, may have a new treatment hope thanks to a novel inhibitor of TNIK, a kinase newly implicated in fibrosis, identified using generative AI drug discovery platforms in just 18 months.
Researchers at Insilico Medicine, along with international collaborators, harnessed the power of AI platforms PandaOmics and Chemistry42 to make a breakthrough discovery. Nature Biotechnology recently published the group’s findings, showcase the potential of AI to accelerate drug discovery. The scientists identified TNIK as a promising therapeutic target for fibrotic diseases and developed INS018_055, a potent TNIK inhibitor. Preclinical models demonstrated INS018_055’s superior anti-fibrotic and anti-inflammatory effects compared to current treatments.
Beyond fibrotic diseas…